Market Research Logo

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2018

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn’s Disease (Regional Enteritis) - Pipeline Review, H2 2018, provides an overview of the Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn’s Disease (Regional Enteritis) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 12, 23, 32, 57, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 2 molecules, respectively.

Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Regional Enteritis) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn’s Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn’s Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn’s Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn’s Disease (Regional Enteritis) (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn’s Disease (Regional Enteritis) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Crohn’s Disease (Regional Enteritis) - Overview
Crohn’s Disease (Regional Enteritis) - Therapeutics Development
Crohn’s Disease (Regional Enteritis) - Therapeutics Assessment
Crohn’s Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
Crohn’s Disease (Regional Enteritis) - Drug Profiles
Crohn’s Disease (Regional Enteritis) - Dormant Projects
Crohn’s Disease (Regional Enteritis) - Discontinued Products
Crohn’s Disease (Regional Enteritis) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Crohn’s Disease (Regional Enteritis), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Products under Development by Companies, H2 2018 (Contd..7), H2 2018
Products under Development by Companies, H2 2018 (Contd..8), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by 4D Pharma PLC, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Adello Biologics LLC, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by AlfaSigma SpA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Allergan Plc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Alpha Cancer Technologies Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Alteogen Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Alvotech Iceland, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Amgen Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Antibe Therapeutics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Aptevo Therapeutics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Artelo Biosciences Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Arven Ilac, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Atlantic Bio Sci LLC, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Atlantic Healthcare Plc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Avexegen Therapeutics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Bioleaders Corp, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by BioLingus AG, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Biond Biologics Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Bristol-Myers Squibb Co, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Celgene Corp, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Celltrion Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by ChemoCentryx Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Coherus BioSciences Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Commence Bio Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Concenter BioPharma Silkim Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by DBV Technologies SA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by EA Pharma Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Eisai Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Eli Lilly and Co, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Enzo Biochem Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by ETX Pharma Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Evelo Biosciences Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Ferring International Center SA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Fresenius SE & Co KGaA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by FYB202 GmbH & Co KG, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Galactica Biotech Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Galapagos NV, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Genentech Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by IB Pharmaceuticals Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Inception Sciences Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by InDex Pharmaceuticals Holding AB, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Innovation Pharmaceuticals Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Innovent Biologics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Inspyr Therapeutics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Jyant Technologies Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Kang Stem Biotech Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Merck & Co Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Mesoblast Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Naia Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Nimbus Therapeutics LLC, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Oncobiologics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by OSE Immunotherapeutics, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Pfizer Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Protagonist Therapeutics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Protheragen Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Re-Pharm Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Sandoz International GmbH, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by SATT North SAS, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Scythian Biosciences Corp, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Second Genome Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Seres Therapeutics Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Shire Plc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Soligenix Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Sublimity Therapeutics Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Synedgen Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Synlogic Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Tetherex Pharmaceuticals Corp, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by The Cell-Factory BVBA, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Theravance Biopharma Inc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Thetis Pharmaceuticals LLC, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Vivelix Pharmaceuticals Ltd, H2 2018
Crohn’s Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..2), H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..3), H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..4), H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..5), H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..6), H2 2018
Crohn’s Disease (Regional Enteritis) - Dormant Projects, H2 2018 (Contd..7), H2 2018
Crohn’s Disease (Regional Enteritis) - Discontinued Products, H2 2018
Crohn’s Disease (Regional Enteritis) - Discontinued Products, H2 2018 (Contd..1), H2 2018
List of Figures
Number of Products under Development for Crohn’s Disease (Regional Enteritis), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report